http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
-
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
-
Fulcrum Therapeutics Inc. (FULC) Announces FDA Lifted Clinical Hold on FTX-6058 for Sickle Cell Disease
-
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
-
Fulcrum Therapeutics Inc. (FULC) Appoints Alan A. Musso as CFO
-
Fulcrum Therapeutics Appoints Chief Financial Officer
-
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
-
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important June 27 Deadline in Securities Class Action – FULC
-
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action – FULC
-
ROSEN, A LEADING NATIONAL FIRM, Encourages Fulcrum Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FULC
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FULC
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
-
Fulcrum Therapeutics (FULC) Appoints Alex C. Sapir as CEO
-
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
-
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
-
Fulcrum Therapeutics Inc. (FULC) Provides Business Update, 2023 Outlook
-
Fulcrum Therapeutics Inc. (FULC) CEO Bryan Stuart to retire, names Robert Gould as interim CEO
-
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
-
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
-
Fulcrum Therapeutics Announces CEO Transition
-
Fulcrum Therapeutics Announces CEO Transition
-
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
-
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
-
Fulcrum Therapeutics Inc. (FULC) Appoints Santiago Arroyo as Chief Medical Officer and Jeff W. Jacobs as Chief Scientific Officer
-
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
-
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
-
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
-
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
-
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
-
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
-
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
-
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
